Despite therelatively low expression of these Ephs in the NSCLC cells examined compared to EphA2, Ephrin B3 may still act via these to exert some of its effect and thus blocking Ephrin B3 could also potentially target these Ephs. The gene discussed is EPHA2; the disease is non-small cell lung carcinoma.